Evidence map›Paper›PMID 35855959›Full record

ArticleOpen forum infectious diseases2022

CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.

Megha L Mehrotra, Esther Lim, Katherine Lamba, Amanda Kamali, Kristina W Lai, Erika Meza, Irvin Szeto, Peter Robinson, Cheng-Ting Tsai, David Gebhart and 8 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Megha L MehrotraCalifornia Department of Public Health, Epidemiology, Surveillance and Modeling Section, COVID-19 Response, Richmond, California, USA.ORCID https://orcid.org/0000-0003-1748-8690
Esther LimCalifornia Department of Public Health, Epidemiology, Surveillance and Modeling Section, COVID-19 Response, Richmond, California, USA.
Katherine LambaCalifornia Department of Public Health, Epidemiology, Surveillance and Modeling Section, COVID-19 Response, Richmond, California, USA.
Amanda KamaliCalifornia Department of Public Health, Epidemiology, Surveillance and Modeling Section, COVID-19 Response, Richmond, California, USA.
Kristina W LaiCalifornia Department of Public Health, Epidemiology, Surveillance and Modeling Section, COVID-19 Response, Richmond, California, USA.
Erika MezaCalifornia Department of Public Health, Epidemiology, Surveillance and Modeling Section, COVID-19 Response, Richmond, California, USA.
Irvin SzetoInfectious Diseases, Stanford University, School of Medicine, Palo Alto, California, USA.
Peter RobinsonEnable Biosciences, South San Francisco, California, USA.
Cheng-Ting TsaiEnable Biosciences, South San Francisco, California, USA.
David GebhartEnable Biosciences, South San Francisco, California, USA.
Noemi FonsecaEnable Biosciences, South San Francisco, California, USA.
Andrew B MartinInfectious Diseases, Stanford University, School of Medicine, Palo Alto, California, USA.
Catherine LeyInfectious Diseases, Stanford University, School of Medicine, Palo Alto, California, USA.
Steve ScherfGauss Surgical, Menlo Park, California, USA.
James WattCalifornia Department of Public Health, Epidemiology, Surveillance and Modeling Section, COVID-19 Response, Richmond, California, USA.
David SeftelEnable Biosciences, South San Francisco, California, USA.
Julie ParsonnetInfectious Diseases, Stanford University, School of Medicine, Palo Alto, California, USA.ORCID https://orcid.org/0000-0001-7342-5366
Seema JainCalifornia Department of Public Health, Epidemiology, Surveillance and Modeling Section, COVID-19 Response, Richmond, California, USA.ORCID https://orcid.org/0000-0002-6342-8288

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Understanding the distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies from vaccination and/or prior infection is critical to the public health response to the pandemic. CalScope is a population-based serosurvey in 7 counties in California. Methods: We invited 200 000 randomly sampled households to enroll up to 1 adult and 1 child between April 20, 2021 and June 16, 2021. We tested all specimens for antibodies against SARS-CoV-2 nucleocapsid and spike proteins, and each participant completed an online survey. We classified participants into categories: seronegative, antibodies from infection only, antibodies from infection and vaccination, and antibodies from vaccination only. Results: A total of 11 161 households enrolled (5.6%), with 7483 adults and 1375 children completing antibody testing. As of June 2021, 33% (95% confidence interval [CI], 28%-37%) of adults and 57% (95% CI, 48%-66%) of children were seronegative; 18% (95% CI, 14%-22%) of adults and 26% (95% CI, 19%-32%) of children had antibodies from infection alone; 9% (95% CI, 6%-11%) of adults and 5% (95% CI, 1%-8%) of children had antibodies from infection and vaccination; and 41% (95% CI, 37%-45%) of adults and 13% (95% CI, 7%-18%) of children had antibodies from vaccination alone. Conclusions: As of June 2021, one third of adults and most children in California were seronegative. Serostatus varied regionally and by demographic group.

Indexed as

population-basedSARS-CoV-2 seroprevalence

Identifiers

PMID35855959
PMCPMC9129171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.